An exploratory study on the applied dose of remimazolam during the induction of general anesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056641

Enrollment

Unknown

Registered

2022-02-09

Start date

2022-02-07

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

effective induction dose in obese population

Interventions

Group MTBW:receive remimazolam via infusion based on TBW

Group MLBW:receive remimazolam via infusion based on LBW

Group CTBW:receive remimazolam via infusion based on TBW

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria of morbid obesity group: 1. Aged 18-65 years; 2. BMI >= 35kg/m2 3. Patients who need general anesthesia for elective surgery; 4. ASA II III; 5. Malampati is classified as Grade I to III; 6. The patient voluntarily participated in this study and signed the informed consent form. Inclusion criteria for normal weight control group: 1. Aged 18-65 years; 2.18.5kg/m2<=BMI <= 23kg/m2; 3. Patients who need general anesthesia for elective surgery; 4. ASA Class I to III; 5. Malampati is classified as Grade I to III; 6. The patient voluntarily participated in this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergic to benzodiazepines and any component of remidazolam toluenesulfonate; 2. Patients with long-term use of narcotic analgesics, non-steroidal anti-inflammatory drugs and benzodiazepine hypnotics; 3. Cardiac function above level 3; 4. Participated in drug clinical trials as a subject in the past three months; 5. Pregnancy, lactation, possible pregnancy and planned pregnancy; 6. History of abnormal anesthesia recovery in previous operations: intraoperative awareness history, postoperative delirium history; 7. Patients who have a history of difficult tracheal intubation and plan to undergo conscious fiberoptic bronchoscopy intubation before operation.

Design outcomes

Primary

Measure	Time frame
Total remimazolam induction dose of loss of conscioueness;	—

Secondary

Measure	Time frame
Time of loss of consciousness;BIS value of loss of consciousness;The proportion of SBP decreased compared with basic SBP when LOC;	—

Countries

China

Contacts

Public ContactYuan Han

Eye & ENT Hospital of Fudan University

hanyuan@eentanesthesia.com+86 21 64377134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 3, 2026